Authors : Sivane Sunilkumar; Dr. G. Ariharasivakumar

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/3kj643js

Scribd : https://tinyurl.com/mmayfzxy

DOI : https://doi.org/10.38124/ijisrt/25aug908

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor and non-motor impairments. Despite advancements in treatment, current therapies remain largely palliative, failing to address disease progression. A major challenge in PD treatment is the restricted delivery of therapeutics across the blood-brain barrier (BBB). Nanotechnology, particularly lipid nanoparticles (LNPs), offers a promising drug delivery approach due to their biocompatibility, controlled release, and ability to enhance BBB penetration. LNPs can encapsulate various therapeutic agents, including small molecules, proteins, and RNA-based therapies, offering potential disease-modifying effects. Preclinical studies demonstrate that LNPs improve drug bioavailability, target specificity, and therapeutic efficacy. Additionally, modifications such as PEGylation and ligand conjugation (e.g., transferrin, angiopep-2) further enhance brain-targeted delivery. While LNPs have been successfully applied in vaccine and gene therapy development, their potential in PD treatment remains underexplored, with limited clinical trials. Future research should focus on optimizing LNP formulations for brain-specific delivery, leveraging genetic therapies like RNA interference, and translating preclinical findings into clinical applications. This review highlights the transformative potential of LNP-based nanomedicine in PD treatment, paving the way for more effective and targeted therapeutic strategies.

Keywords : Parkinson ‘s Disease, Neurological Disorders, BBB, LNPs.

References :

1. Mani M, Balasubramanian S, Manikandan KR, Kulandaivel B. Neuroprotective potential of Naringenin-loaded solid-lipid nanoparticles against rotenone-induced Parkinson’s disease model. Journal of Applied Pharmaceutical Science. 2021 Feb 5;11(2):019-28.
2. Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. International journal of molecular sciences. 2022 Feb 6;23(3):1851.
3. Milnerwood, A.J.; Raymond, L.A. Early synaptic pathophysiology in neurodegeneration: Insights from Huntington’s disease. Trends Neurosci. 2010, 33, 513–523.
4. Dumurgier J, Tzourio C. Epidemiology of neurological diseases in older adults. Revue neurologique. 2020 Nov 1;176(9):642-8.
5. Omidi Y, Barar J. 2012. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts. 2(1): 5–22
6. Achar A, Myers R, Ghosh C. Drug delivery challenges in brain disorders across the blood–brain barrier: novel methods and future considerations for improved therapy. Biomedicines. 2021 Dec 4;9(12):1834.
7. Bodor n, Buchwald n. 1999. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev. 36(2–3):229–254.
8. Cai H, Liu D, Xue WW, Ma L, Xie HT, Ning K. Lipid-based nanoparticles for drug delivery in Parkinson’s disease. Translational Neuroscience. 2024 Dec 3;15(1):20220359.
9. Nishijima H, Kimura T, Mori F, Wakabayashi K, Kinoshita I, Nakamura T, Kon T, Suzuki C, Tomiyama M. Effects of Aging on Levo-Dihydroxyphenylalanine-Induced Dyskinesia in a Rat Model of Parkinson’s Disease. Frontiers in Aging Neuroscience. 2021 May 13; 13:650350.
10. Campos FL, Carvalho MM, Cristovão AC, Je G, Baltazar G, Salgado AJ, Kim YS, Sousa N. Rodent models of Parkinson's disease: beyond the motor symptomatology. Frontiers in behavioral neuroscience. 2013 Nov 26; 7:175.
11. Simon, D.K.; Tanner, C.M.; Brundin, P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin. Geriatr. Med. 2019, 36, 1–12
12. Dickson, D.M. Neuropathology of Parkinson disease. Parkinsonism Relat. Disord. 2018, 46, S30–S33.
13. Soreq, L.; Bergman, H.; Israel, Z.; Soreq, H. Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson’s patients’ leukocytes. BMC Genomics 2013, 14, 478.
14. Zhu,J.; Chu, C.T. Mitochondrial dysfunction in Parkinson’s disease. J. Alzheimers Dis. 2010, 20, S325–S334.
15. Mudshinge, S.R.; Deore, A.B.; Patil, S.; Bhalgat, C.M. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm. J. 2011, 19, 129–141
16. Sci. 2018, 4, 191–205. [CrossRef] 89. Chakraborty, S.; Dhakshinamurthy, G.S.; Misra, S.K. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications. J. Biomed. Mater. Res. A 2017, 105, 2906–2928.
17. onge-Fuentes, V.; Biolchi Mayer, A.; Lima, M.R.; Geraldes, L.R.; Zanotto, L.N.; Moreira, K.G.; Martins, O.P.; Piva, H.L.; Felipe, M.S.S.; Amaral, A.C.; et al. Dopamine-loaded nanoparticle systems circumvent the blood–brain barrier restoring motor function in mouse model for Parkinson’s Disease. Sci. Rep. 2021, 11, 15185.
18. Qu, M.; Lin, Q.; He, S.; Wang, L.; Fu, Y.; Zhang, Z.; Zhang, L. A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson’s disease. J. Control. Release 2018, 277, 173–182
19. Gong C, Li X, Xu L, Zhang YH. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide. Biomaterials. 2012 Apr 1;33(12):3456-63.
20. Dudhipala, N.; Gorre, T. Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for Parkinson’s disease: In vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics 2020, 12, 488.
21. ClinicalTrials.gov. Available online:https://clinicaltrials.gov/ct2/results?cond=Parkinson+Disease&term=liposomes (accessed on 27 July 2022).
22. ClinicalTrials.gov. Available online:https://clinicaltrials.gov/ct2/results?recrs=&cond=Parkinson+Disease&term=nanoparticles (accessed on 27 July 2022).
23. Silva, S.; Almeida, A.J.; Vale, N. Importance of nanoparticles for the delivery of antiparkinsonian drugs. Pharmaceutics 2021, 13, 508.
24. Urits, I.; Swanson, D.; Swett, M.C.; Patel, A.; Berardino, K.; Ariunzaya Amgalan, A.; Berger, A.A.; Kassem, H.; Kaye, A.D.; Viswanath, O. A review of Patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 2020, 9, 301–315.
25. Jagaran K, Singh M. Lipid nanoparticles: promising treatment approach for Parkinson’s disease. International Journal of Molecular Sciences. 2022 Aug 19;23(16):9361.